Work

BXCL701 plus pembrolizumab in second-line advanced pancreatic ductal adenocarcinoma: Final outcomes of the EXPEL PANC trial.

Year: 2026

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2026.44.16_suppl.4201

Authors: Benjamin Adam Weinberg, Alexander Lekan, Zoe Malchiodi, Allison Fitzgerald, Ming Tony Tan, Xue Geng, Marcus Smith Noel, Aiwu Ruth He, Reetu Mukherji, John L. Marshall, Martin Gutierrez, Princess Jones, Rashmi Majali Deshpande, Louis M. Weiner

Institutions: Georgetown University, Georgetown University Medical Center, Georgetown Lombardi Comprehensive Cancer Center, Dana-Farber Cancer Institute, Columbia University Irving Medical Center, Hackensack University Medical Center, BioXcel Therapeutics, Inc. (United States)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7162491198

Cites:

Cited by:

Related to: